MX369317B - Vacunas contra el virus de la influenza y sus usos. - Google Patents

Vacunas contra el virus de la influenza y sus usos.

Info

Publication number
MX369317B
MX369317B MX2015016382A MX2015016382A MX369317B MX 369317 B MX369317 B MX 369317B MX 2015016382 A MX2015016382 A MX 2015016382A MX 2015016382 A MX2015016382 A MX 2015016382A MX 369317 B MX369317 B MX 369317B
Authority
MX
Mexico
Prior art keywords
domain
amino acids
terminal
influenza virus
influenza hemagglutinin
Prior art date
Application number
MX2015016382A
Other languages
English (en)
Other versions
MX2015016382A (es
Inventor
Anthony Williamson Robert
Wadia Jehangir
Radosevic Katarina
IMPAGLIAZZO Antonieta
Wilem Meijberg Jan
Wagner Michelle
Ding Zhaoqing
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2015016382A publication Critical patent/MX2015016382A/es
Publication of MX369317B publication Critical patent/MX369317B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Abstract

La presente invención se refiere a polipéptidos con dominio de tallo de hemaglutinina de influenza que comprenden (a) un dominio HA1 de hemaglutinina de influenza que comprende un segmento de tallo N-terminal de HA1, que comprende los aminoácidos de la posición 1 a la posición x, preferentemente de la posición p a la posición x, del dominio HA1, unido covalentemente mediante una secuencia de enlace de 0-50 residuos de aminoácido a un segmento de tallo C-terminal de HA1, que comprende los aminoácidos de la posición y hasta e incluyendo el aminoácido C-terminal del dominio HA1 y (b) un dominio HA2 de hemaglutinina de influenza, donde el polipéptido con dominio de tallo de hemaglutinina es resistente a la escisión de proteasas en el empalme entre HA1 y HA2, y donde uno o más aminoácidos de los aminoácidos en las posiciones 337, 340, 352, 353, 402, 406, 409, 413 y/o 416 han sido mutados en comparación con las posiciones correspondientes en la HA de influenza de tipo natural.
MX2015016382A 2013-05-30 2014-05-27 Vacunas contra el virus de la influenza y sus usos. MX369317B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13169830 2013-05-30
PCT/EP2014/060997 WO2014191435A1 (en) 2013-05-30 2014-05-27 Influenza virus vaccines and uses thereof

Publications (2)

Publication Number Publication Date
MX2015016382A MX2015016382A (es) 2016-10-14
MX369317B true MX369317B (es) 2019-11-05

Family

ID=48485075

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016382A MX369317B (es) 2013-05-30 2014-05-27 Vacunas contra el virus de la influenza y sus usos.

Country Status (17)

Country Link
US (1) US10517941B2 (es)
EP (1) EP3004142B1 (es)
JP (1) JP6643981B2 (es)
KR (1) KR102252163B1 (es)
CN (1) CN105452270B (es)
AU (1) AU2014273173B2 (es)
BR (1) BR112015029635B1 (es)
CA (1) CA2913859C (es)
EA (1) EA034639B1 (es)
HK (1) HK1223110A1 (es)
IL (1) IL242824B (es)
MX (1) MX369317B (es)
MY (1) MY190097A (es)
PH (1) PH12015502612B1 (es)
SG (1) SG11201509663PA (es)
WO (1) WO2014191435A1 (es)
ZA (1) ZA201509229B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012343981B2 (en) 2011-11-28 2017-09-07 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
CN105452270B (zh) 2013-05-30 2020-12-01 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
EP3916390A1 (en) * 2014-06-04 2021-12-01 Indevr, Inc. Universal capture array for multiplexed subtype-specific quantification and stability determination of influenza proteins
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
NZ727024A (en) 2014-06-26 2022-02-25 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EA038400B1 (ru) * 2014-07-10 2021-08-23 Янссен Вэксинс Энд Превеншн Б.В. Полипептид стеблевого домена гемагглютинина вируса гриппа и его применение
JP7094103B2 (ja) 2014-07-10 2022-07-01 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチンおよびその使用
SG11201901790YA (en) * 2016-09-02 2019-03-28 The Usa As Represented By The Secretary Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JP2020519666A (ja) 2017-05-15 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定性のウイルス含有組成物
US11945841B2 (en) 2017-10-04 2024-04-02 Gerogia State University Research Foundation, Inc. Headless hemagglutin influenza vaccine
PE20210651A1 (es) * 2018-01-23 2021-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de la gripe y usos de las mismas
CA3152957A1 (en) 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2023154841A2 (en) * 2022-02-11 2023-08-17 The Texas A&M University System Sars-cov-2 neutralizing synthetic proteins
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
MX2009002174A (es) 2006-09-07 2009-03-12 Crucell Holland Bv Moleculas de union humanas capaces de neutralizar el virus de la influenza h5n1 y usos de las mismas.
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
ES2934102T3 (es) 2009-05-11 2023-02-16 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden neutralizar el virus de la gripe H3N2 y usos de las mismas
EP3900740A1 (en) 2010-03-30 2021-10-27 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
CA2838999C (en) 2011-07-14 2021-02-16 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
AU2012343981B2 (en) * 2011-11-28 2017-09-07 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
CN105452270B (zh) 2013-05-30 2020-12-01 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
JP7094103B2 (ja) 2014-07-10 2022-07-01 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチンおよびその使用
EA038400B1 (ru) 2014-07-10 2021-08-23 Янссен Вэксинс Энд Превеншн Б.В. Полипептид стеблевого домена гемагглютинина вируса гриппа и его применение

Also Published As

Publication number Publication date
PH12015502612A1 (en) 2016-02-29
JP2016525889A (ja) 2016-09-01
NZ715583A (en) 2021-02-26
AU2014273173A1 (en) 2015-12-10
SG11201509663PA (en) 2015-12-30
CN105452270A (zh) 2016-03-30
EA201592306A1 (ru) 2016-05-31
CA2913859C (en) 2021-11-30
CN105452270B (zh) 2020-12-01
PH12015502612B1 (en) 2016-02-29
KR102252163B1 (ko) 2021-05-14
MY190097A (en) 2022-03-28
US20160136262A1 (en) 2016-05-19
MX2015016382A (es) 2016-10-14
BR112015029635A2 (pt) 2017-09-26
CA2913859A1 (en) 2014-12-04
WO2014191435A1 (en) 2014-12-04
US10517941B2 (en) 2019-12-31
EP3004142B1 (en) 2020-09-30
BR112015029635B1 (pt) 2023-05-02
ZA201509229B (en) 2022-03-30
EP3004142A1 (en) 2016-04-13
HK1223110A1 (zh) 2017-07-21
AU2014273173B2 (en) 2018-09-27
JP6643981B2 (ja) 2020-02-12
EA034639B1 (ru) 2020-03-02
IL242824B (en) 2020-07-30
KR20160013205A (ko) 2016-02-03

Similar Documents

Publication Publication Date Title
PH12015502612B1 (en) Influenza virus vaccines and uses thereof
PH12014501118A1 (en) Influenza virus vaccines and uses thereof
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
MX343386B (es) Proteinas de fusion portadoras de peptido como vacunas para alergia.
CO2017004318A2 (es) Variantes de interferon α2b
CY1120578T1 (el) Μιγμα πεπτιδιων
NZ627796A (en) Influenza virus vaccines and uses thereof
PE20170290A1 (es) Vacunas contra virus de influenza y usos de las mismas
AR102865A1 (es) Parejas de fusión para la producción de péptidos
WO2010036970A3 (en) Influenza vaccines, antigens, compositions, and methods
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
RS53851B1 (en) ANTIKANCERSKI PROTEIN FUNCTIONS
MX2018015755A (es) Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
MX340735B (es) Proteinas multimericas recombinantes de la influenza.
MX2016011394A (es) Moleculas de andamiaje a base de fibronectina estabilizada.
JP2015038108A5 (es)
MX2021012991A (es) Antigenos de gripe recombinantes.
MX2017015927A (es) Fragmentos mutantes de proteina ras.
HRP20220980T1 (hr) Cjepiva protiv virusa influence i njihova uporaba
MX2016014633A (es) Nuevos derivados de cath2.
EA201591609A1 (ru) Варианты альфа-амилазы
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
CY1123664T1 (el) Εμβολιο
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.
SG10201908920QA (en) Influenza virus vaccines and uses thereof

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: CENTREXION THERAPEUTICS CORPORATION

FG Grant or registration